Athena Athena

X
[{"orgOrder":0,"company":"Immodulon Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immodulon Announces that IMM-101 will be Evaluated in World-First, Prophylactic Immuneboosting Strategy for COVID-19 in Cancer Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III"},{"orgOrder":0,"company":"Immodulon Therapeutics","sponsor":"Champalimaud Foundation","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Immodulon, Champalimaud Foundation Team Up on \u2018Difficult To Treat\u2019 Cancers","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II"}]

Find Clinical Drug Pipeline Developments & Deals by Immodulon Therapeutics

Menu
Loading...
Filters Filter
×
FILTER:
filter Company
    filter Sponsor
      filter Country
        filter Therapeutic Area
          filter Study Phase

            Active Filter(s):

            Companies By Therapeutic Area

            Development Status

            Details:

            Collaboration will explore clinical trials with IMM-101, in combination with other treatments, in difficult to treat cancers, with a particular focus on epithelial cancers such as pancreatic cancer and sarcoma.

            Lead Product(s): IMM-101

            Therapeutic Area: Oncology Product Name: IMM-101

            Highest Development Status: Phase II Product Type: Large molecule

            Partner/Sponsor/Collaborator: Champalimaud Foundation

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration August 03, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Phase 3 study approved by Health Canada seeks to boost cancer patients’ immune systems with IMM-101 to protect against severe COVID-19 and other viral lung infections.

            Lead Product(s): IMM-101

            Therapeutic Area: Infections and Infectious Diseases Product Name: IMM-101

            Highest Development Status: Phase III Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable July 09, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY